Key Takeaway Epitalon is considered low-risk in clinical research, with most adverse events being minor
[PMC free article] [PubMed] [Google Scholar] 37.Turnbull C.D., Wang S.H., Manuel A.R., Keenan B.T., McIntyre A.G., Schwab R.J., Stradling J.R
Patients typically begin with a low dose of a GLP-1 agonist medication, which is gradually increased for effective weight loss
The peptide functions as a non-selective agonist of melanocortin receptors, specifically MC1R, MC3R, MC4R, and to a lesser extent MC5R
the gut microbiota is now considered an endocrine organ that communicates with the body through the gut-systemic axis and is extensively modifiable by foods 4,5,6